Month: June 2021

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

06/11/2021

Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–As part of the 2021 ASCO Annual Meeting, precision oncology company Lucence is sharing real-world data supporting clinical applications of its amplicon-based liquid biopsy assay. The data will be presented in on-demand virtual poster sessions, available beginning June 4 at 9 AM EDT. Lucence is also announcing…

Read More

Harvard Licenses Technology to Obatala Sciences to Advance Discovery in Obesity, Diabetes, and Cancer

06/11/2021

Excerpt from the Press Release: CAMBRIDGE, Mass. & NEW ORLEANS–(BUSINESS WIRE)–Harvard University has granted an exclusive license to biotechnology company Obatala Sciences to commercialize innovations that enable the study of human fat tissue in vitro. Harvard Office of Technology Development and Obatala, which manufactures stem cell and hydrogel products to enable next-generation therapeutics discovery, announced the agreement today. Obatala…

Read More

Researchers identify potential new targets for next-generation COVID-19 vaccines

06/10/2021

Excerpt from the Press Release: Current COVID-19 vaccines are effective at preventing severe disease, including infection caused by known variants of concern. But new variants of the SARS-CoV-2 virus could potentially evade immunity, so vaccine makers have already started developing next-generation vaccines. Recent research has suggested that new vaccines that more potently stimulate the immune…

Read More

“Electronic Nose” Accurately Sniffs Out Hard-to-Detect Cancers

06/10/2021

Excerpt from the Article: PHILADELPHIA—An odor-based test that sniffs out vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95 percent accuracy, according to a new study from researchers at the University of Pennsylvania and Penn’s Perelman School of Medicine. The findings suggest that the Penn-developed tool…

Read More

Oyster Point Pharma Announces Preclinical Study Results and Pipeline Expansion with Enriched Tear Film (ETF™) Gene Therapy to Target Ocular Surface Diseases

06/09/2021

Excerpt from the Press Release: PRINCETON, N.J., June 03, 2021 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF™) Gene Therapy…

Read More

CureVac’s First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation

06/09/2021

Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / May 28, 2021 / CureVac N.V. (NASDAQ:CVAC), a clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the independent Data Safety Monitoring Board (DSMB) has confirmed that the pivotal Phase 2b/3 study (HERALD)…

Read More

SOPHiA GENETICS Advances Blood Cancer Genomic Testing With New Myeloid Solutions

06/08/2021

Excerpt from the Press Release: BOSTON and LAUSANNE, Switzerland, June 1, 2021 /PRNewswire/ — SOPHiA GENETICS, the creator of a global data-sharing network that advances data-driven medicine, today released SOPHiA DDM™ for Blood Cancers, novel blood cancer testing solutions across the entire workflow from setup, genomic testing, and in-house advanced analytics. The solutions target the most relevant DNA variants and RNA fusion genes…

Read More

uniQure Announces Positive Recommendation to Advance Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease

06/08/2021

Excerpt from the Press Release: LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 27, 2021 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s…

Read More

An expert’s guide to developing medical devices

06/07/2021

Excerpt from the Article: When it comes to designing and building novel medical devices to meet the needs of patients and healthcare systems, developers should rely on the core skills of engineering and design to inform their process. But there are “lessons learned” that are unique to the medical device development process. The team at Goddard has…

Read More

Naveris’ New Saliva Test Detects Head and Neck Cancer

06/07/2021

Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV)…

Read More